Johnson & Johnson Stock Price, News & Analysis

Johnson & Johnson (NYSE: JNJ) reported a fourth-quarter sales decline of 4.4% to $23.7 billion, primarily due to unfavorable foreign exchange and reduced COVID-19 Vaccine sales. However, operational growth excluding vaccine sales reached 4.6%. The 2022 full-year reported sales increased 1.3% to $94.9 billion. Earnings per share (EPS) for Q4 decreased by 24.9% to $1.33, while adjusted EPS increased by 10.3% to $2.35. For 2023, the company expects adjusted operational sales growth of 4.0% and adjusted EPS of $10.50, representing a 3.5% increase.

Biosense Webster, a unit of Johnson & Johnson MedTech, will present findings from five studies on cardiac arrhythmia treatment at the 28th Annual International AF Symposium in Boston from February 2-4. Two late-breaking studies include the multicenter inspIRE study, analyzing a novel pulsed field ablation catheter, and the STELLAR study on a radiofrequency balloon catheter for pulmonary vein isolation. These studies emphasize the company’s commitment to innovation in electrophysiology. Attendees can engage with new technologies at exhibit booth #111, showcasing advanced catheter solutions.

Johnson & Johnson (NYSE: JNJ) will participate in the SVB Securities Global Biopharma Conference on February 15 at 1:00 p.m. Eastern Time. The company will be represented by Biljana Naumovic, Worldwide Vice President, and Peter Lebowitz, Global Therapeutic Head for Oncology, in a virtual session. Investors can access the live audio webcast on the Johnson & Johnson website. A replay will be available approximately 48 hours after the event.

Johnson & Johnson (NYSE: JNJ) has completed its acquisition of Abiomed, Inc., with a transaction value of approximately $16.6 billion, or $380 per share in cash. The acquisition expands J&J's MedTech portfolio, particularly in the high-growth cardiovascular market, and is expected to be slightly dilutive to neutral to adjusted earnings per share in the first year. JJN anticipates this deal will enhance revenue growth in its MedTech segment and yield accretive effects starting in 2024. Abiomed’s stock ceased trading on NASDAQ following the merger on December 22, 2022.

Johnson & Johnson (NYSE: JNJ) has extended the expiration of its offer to acquire Abiomed, Inc. (NASDAQ: ABMD) for $380.00 per share, plus a potential $35.00 contingent value right. The new expiration date is set for December 21, 2022. As of December 13, 2022, about 19.3 million shares, or 42.75% of Abiomed's outstanding shares, have been tendered. The acquisition is conditional on the successful tendering of a majority of shares and receiving necessary regulatory approvals. Investors are encouraged to review related filings on the SEC's website for more details.

Johnson & Johnson (NYSE: JNJ) will host an investor conference call at 8:30 a.m. (Eastern Time) on January 24 to discuss its fourth-quarter results. Key executives, including CEO Joaquin Duato and CFO Joseph J. Wolk, will lead the call. Interested parties can join via the company’s website or by phone. A replay will be available until February 7. The results are anticipated to provide insights into the company’s performance, which is crucial for stakeholders and market analysts.

Johnson & Johnson (NYSE: JNJ) will attend the 41st Annual J.P. Morgan Healthcare Conference on January 9 at 12:45 p.m. ET in San Francisco, CA. CEO Joaquin Duato will represent the company during the session. The event will feature a live audio webcast accessible via the Johnson & Johnson investor website. An audio replay will be available approximately 48 hours after the event.

Johnson & Johnson (NYSE: JNJ) announced that CEO Joaquin Duato will take on the additional role of Chairman, effective January 2023, succeeding Alex Gorsky who steps down after 30 years. Duato, with over three decades at J&J, is recognized for his leadership and commitment to stakeholder value. The transition highlights the company's succession planning, with Duato poised to guide J&J through pivotal times. Both Gorsky's contributions and Duato's vision indicate a strategic focus on healthcare innovation and inclusivity.

ABIOMED, Inc. (NASDAQ: ABMD) reported financial results for the quarter ending September 30, 2022, with revenues reaching $266 million, marking an 11% increase in constant currency. This growth reflects the seventh consecutive quarter of double-digit constant currency growth. U.S. product revenue also increased by 10% to $208 million. However, procedural volumes were affected in July due to physician vacations and labor shortages, which improved by August and September. The company celebrated significant innovation milestones and FDA approvals.